NEW YORK, Nov. 13, 2024 /PRNewswire/ — Fourth Frontier, a medical technology company based out of New York and Bangalore, announced the 510(k) clearance of the Frontier X Plus from the U.S. FDA. The Frontier X Plus is an innovative single-lead, continuous ECG monitor that is worn around…
Author: Ken Dropiewski
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment APC 5734. This approval would allow outpatient settings to receive reimbursement for HeartSciences’ MyoVista® wavECGTM algorithm and MyoVista® InsightsTM low ejection fraction algorithm, upon FDA clearance. The payment rate is expected to be $125.
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
SmartCardia Receives FDA Clearance for Outpatient Cardiac Telemetry for Its 7-Lead ECG Patch and Cloud Platform
LAUSANNE, Switzerland, Nov. 13, 2024 /PRNewswire/ — SmartCardia has received FDA clearance for Mobile Outpatient Cardiac Telemetry (OCT/MCT) for its 7-lead live ECG monitoring patch and cloud platform. SmartCardia’s 7L patch is easy-to-wear, cable-free, waterproof and can be used for…
CorVista Health and ATSS Sign Memorandum of Understanding to Bring Point-of-Care Cardiovascular Diagnostic Platform CorVista® System to the Kingdom of Saudi Arabia
BETHESDA, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) — CorVista Health, Inc., a leading digital health company dedicated to improving cardiovascular disease diagnosis, today announced the signing of a Memorandum of Understanding (MOU) with Advanced Telecommunications Solutions and Services (ATSS) to explore the potential of introducing the CorVista® System into the Kingdom of Saudi Arabia. The CorVista System is the world’s first point-of-care system for evaluating the presence of significant coronary artery disease (CAD) and pulmonary hypertension (PH) in a single visit.
Johnson & Johnson MedTech Receives IDE Approval for OTTAVA™ Robotic Surgical System
Company prepares to support clinical trial in the United States NEW BRUNSWICK, N.J., Nov. 12, 2024 /PRNewswire/ — Johnson & Johnson MedTech, a global leader in cardiovascular, orthopaedic, surgery and vision solutions, today announced that the U.S. Food & Drug Administration (FDA) has…
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome AOC 1072 and AOC 1086 preclinical data…
DataFirst and Everlight Radiology Join Forces to Revolutionize Radiology Services
Driving Intelligence in Enterprise Imaging RALEIGH, N.C., Nov. 12, 2024 /PRNewswire/ — DataFirst and Everlight Radiology are excited to announce a new technology partnership. Everlight Radiology’s sterling reputation for high-quality radiology reporting, combined with DataFirst’s…
Bunkerhill Health AI Powers Cardiovascular Screening at Stamford Health
SAN FRANCISCO, Oct. 21, 2024 /PRNewswire/ — Stamford Health’s Heart & Vascular Institute has announced it will be the first in Connecticut to offer a new, AI-powered cardiovascular screening algorithm to enhance cardiovascular care for its patients. The tool, provided by Bunkerhill…
Stereotaxis Reports 2024 Third Quarter Financial Results
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024.



